Beraprost Therapy in Children with Pulmonary Hypertension Secondary to Congenital Heart Disease

Abstract

We present a report on children with severe pulmonary hypertension secondary to congenital heart disease who received 6 months of beraprost therapy. The children had an increase in intracardiac left-to-right shunt and a reduction of the pulmonary-to-systemic vascular resistance ratio, whereas the pulmonary artery pressure was not significantly changed.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Akiba T, Miyazaki M, Toda N (1986) Vasodilator actions of TRK-100, a new prostaglandin I2 analogue. Br J Pharmacol 89:703–711

    CAS  PubMed  Google Scholar 

  2. 2.

    Barst RJ, Ivy D, Dingemanse J, et al. (2003) Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73:372–382

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Barst R, McGoon M, McLaughlin V, et al. (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Barst RJ, Rubin LJ, Long WA, et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Barst RJ, Rubin LJ, McGoon MD, et al. (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121:409–415

    CAS  PubMed  Google Scholar 

  6. 6.

    Bush A, Busst CM, Shinebourne EA (1985) The use of oxygen and prostacyclin as pulmonary vasodilators in congenital heart disease. Int J Cardiol 9:267–274

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Christensen DD, McConnell ME, Book WM, Mahle WT (2004) Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cadiol 94:261–263

    CAS  Google Scholar 

  8. 8.

    Galie N, Humbert M, Vachiery J, et al. (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo controlled trial J Am Coll Cardiol 39:1496–1502

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Haneda K, Sato N, Togo T, et al. (1994) Late results after correction of ventricular septal defect with severe pulmonary hypertension. Tohoku J Exp Med 174:41–48

    CAS  PubMed  Google Scholar 

  10. 10.

    Higenbottam TW, Spiegelhalter D, Scott JP, et al. (1993) Prostacyclin (epoprostenol) and heart–lung transplanation as treatments for severe pulmonary hypertension. Br Heart J 70:366–370

    CAS  PubMed  Google Scholar 

  11. 11.

    Humbert M, Simonneau G (2004) Sildenafil for pulmonary arterial hypertension; still waiting for evidence. Am J Respir Crit Care Med 169:6–7

    PubMed  Google Scholar 

  12. 12.

    Ichida F, Uese K, Hashimoto I, et al. (1997) Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children. J Cardiol 29:217–224

    CAS  PubMed  Google Scholar 

  13. 13.

    Ichida F. Uses K, Tsubata S, et al. (1997) Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 80:662–664

    CAS  PubMed  Google Scholar 

  14. 14.

    Ichida F, Uese K, Tsubata S, et al. (1998) Beneficial effect of an oral analog of prostacyclin on pulmonary hypertension secondary to congenital heart disease. Cardial Youn 8:205–210

    Google Scholar 

  15. 15.

    Limsuwan A, Platoshyn O, Yu Y, et al. (2001) Inhibition of K+ channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease. Pediatrie Res 50:23–28

    CAS  Google Scholar 

  16. 16.

    McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S (1999) Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130:740–743

    CAS  PubMed  Google Scholar 

  17. 17.

    McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273–277

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Nagaya N, Uematsu M, Okano Y, et al. (1999) Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 34:118–192

    Article  Google Scholar 

  19. 19.

    Ono F, Nagaya N, Kyotani S, et al. (2003) Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ J 67:375–378

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Rabinovitch M (1995) Pathophysiology of pulmonary hypertension. In: Emmanouilides GC, Riemenschneider TA, Alien HD, Gutgesell HP (eds) Moss and Adams Heart Disease in Infants, Children and Adolescents, 5th ed. Williams & Wilkins, Baltimore, pp 1659–1695

    Google Scholar 

  21. 21.

    Rosenzweig E, Kerstein D, Barst R (1999) Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99:1858–1865

    CAS  PubMed  Google Scholar 

  22. 22.

    Rubin U, Mendoza J, Hood M, et al. (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485–491

    CAS  PubMed  Google Scholar 

  23. 23.

    Saji T, Ozawa Y, Ishikita T, Matsuura H, Mastsuo N (1996) Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 78:244–247

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Selzer A, Sudrann RB (1958) Reliability of the determination of cardiac output in man by means of the Fick’s principle. Circ Res 6:485–490

    CAS  PubMed  Google Scholar 

  25. 25.

    Shapiro SM, Qudiz RJ, Cao T, et al. (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30:343–349

    Article  CAS  PubMed  Google Scholar 

  26. 26.

    Toda N (1988) Beraprost sodium. Cardio Drug-Rev 6:222–238

    Google Scholar 

  27. 27.

    Umetsu T, Murata T, Nishio S (1989) Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneim Forsch 39:68–73

    CAS  Google Scholar 

  28. 28.

    Vizza C, Sciomer S, Morelli S, et al. (2001) Long-term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 86:661–665

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Wagenvoort CA, Wagenvoort N (1979) Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol 11:123–130

    Google Scholar 

Download references

Acknowledgments

We thank the cardiac catheterization laboratory staff at Ramathibodi Hospital for facilitating the study and the Ramathibodi metabolic ward staff for assisting with patient care. This work was supported by grants from the Cardiac Children Foundation of Thailand.

Author information

Affiliations

Authors

Corresponding author

Correspondence to A. Limsuwan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Limsuwan, A., Pienvichit, P. & Khowsathit, P. Beraprost Therapy in Children with Pulmonary Hypertension Secondary to Congenital Heart Disease. Pediatr Cardiol 26, 787–791 (2005). https://doi.org/10.1007/s00246-005-0925-4

Download citation

Keywords

  • Pulmonary hypertension
  • Congenital heart disease
  • Eisenmenger syndrome